Thrombocytopenia (General Approach)

📋 Key Information Summary

📋

Definition: Thrombocytopenia is a platelet count <150 × 10⁹/L; clinically significant bleeding risk increases below 20–30 × 10⁹/L.
Always exclude pseudothrombocytopenia first — repeat full blood count (FBC) in a citrate tube and/or examine a fresh blood film for platelet clumping before initiating a workup.
Three broad mechanisms: decreased production (marrow failure), increased destruction (immune or non-immune), and sequestration (hypersplenism) — the clinical context determines the most likely cause.
Medication history is paramount — heparin (HIT), valproate, cotrimoxazole, linezolid, glycoprotein IIb/IIIa inhibitors, and many other drugs can cause thrombocytopenia.
Heparin-induced thrombocytopenia (HIT) should be suspected with any platelet fall >50% occurring 5–14 days after heparin exposure; stop heparin immediately and order PF4/heparin ELISA.
Initial laboratory evaluation includes FBC with blood film, coagulation profile, LFTs, renal function, LDH, and viral serology (HIV, HCV ± HBV); consider B12/folate if macrocytosis is present.
Red flags requiring emergency referral: platelets <20–30 × 10⁹/L with active bleeding, suspected TTP/HUS (thrombocytopenia + microangiopathic haemolytic anaemia ± neurological/renal features), DIC, or features of acute leukaemia.
Thrombotic thrombocytopenic purpura (TTP) is a medical emergency — do NOT wait for ADAMTS13 results before initiating plasma exchange; give high-dose corticosteroids concurrently.
Stable, asymptomatic patients with platelets >30 × 10⁹/L and no bleeding may be observed with serial FBCs while the underlying cause is investigated.
Refer to haematology for persistent (>4 weeks), unexplained, or recurrent thrombocytopenia, or if the aetiology remains unclear after initial workup.
Aboriginal and Torres Strait Islander Australians have higher rates of chronic liver disease, hepatitis B/C, Helicobacter pylori infection, and rheumatic heart disease — all contributing to thrombocytopenia — and require culturally safe, community-based follow-up.
Avoid unnecessary platelet transfusions in immune-mediated thrombocytopenia (e.g. ITP, TTP) unless life-threatening bleeding is present, as transfused platelets are rapidly destroyed and may worsen thrombosis in TTP.

Introduction & Australian Epidemiology

Thrombocytopenia — defined as a peripheral platelet count below 150 × 10⁹/L — is one of the most commonly encountered haematological abnormalities in Australian primary care and hospital practice. It ranges from an incidental, clinically insignificant finding to a life-threatening emergency. A systematic approach is essential to avoid misdiagnosis (particularly pseudothrombocytopenia), identify reversible causes, and ensure timely referral when red-flag features are present.

In Australian population studies, mild thrombocytopenia (platelets 100–150 × 10⁹/L) is found in approximately 5–7% of routine pathology requests. Moderate-to-severe thrombocytopenia (platelets <100 × 10⁹/L) is less common and more frequently associated with an identifiable cause. The most prevalent aetiologies in Australian settings include chronic liver disease (particularly non-alcoholic fatty liver disease and alcohol-related liver disease), medication-induced thrombocytopenia, immune thrombocytopenia (ITP), and infection-related causes.

Heparin-induced thrombocytopenia (HIT) occurs in approximately 1–3% of patients exposed to unfractionated heparin and is a significant cause of hospital-acquired thrombocytopenia in Australia. Systemic infections, including HIV and hepatitis C, remain important treatable causes, with higher prevalence in certain populations. Aboriginal and Torres Strait Islander Australians experience disproportionate rates of chronic liver disease and hepatitis B, contributing to a higher burden of thrombocytopenia in these communities.

Immune thrombocytopenia (ITP) has an estimated incidence of 3.3 per 100,000 adults per year in Australia, with a slight female predominance in younger adults and a peak in those over 60 years. Thrombotic thrombocytopenic purpura (TTP) is rare (approximately 4–6 cases per million per year) but carries a mortality exceeding 90% if untreated, underscoring the importance of early recognition.

This guideline provides a structured general approach to the adult patient presenting with thrombocytopenia, with emphasis on excluding pseudothrombocytopenia, identifying reversible causes, recognising red-flag syndromes, and ensuring appropriate referral within the Australian healthcare context.

Rule Out Pseudothrombocytopenia

Pseudothrombocytopenia (spurious thrombocytopenia) accounts for up to 0.1–0.2% of all automated FBC results and must be excluded before any further investigation is undertaken. Failure to recognise it leads to unnecessary testing, inappropriate treatment, and patient anxiety.

Mechanisms of Pseudothrombocytopenia

Mechanism	Description	Action
EDTA-dependent platelet clumping	Most common cause. Anti-platelet antibodies in plasma cause aggregation in EDTA anticoagulant, leading to falsely low automated count.	Repeat FBC in a citrate (blue-top) tube.
Giant platelets	Very large platelets (e.g. in MYH9-related disorders, Bernard-Soulier syndrome) may be counted as red cells by analysers.	Manual blood film review to assess platelet size.
Platelet satellitism	Platelets adhere to leucocytes (usually neutrophils) in vitro; rare, usually EDTA-dependent.	Citrate tube repeat and/or manual film.
In vitro clotting	Partial clot in the sample traps platelets.	Recollection with good venepuncture technique.

⚠️

Before initiating a thrombocytopenia workup: Always request a repeat FBC in a citrate tube and/or ask the laboratory to prepare a fresh blood film to exclude platelet clumping. If the citrate-tube platelet count is normal, pseudothrombocytopenia is confirmed and no further investigation is required.

Step-by-Step Approach

1

Recognise unexpected result

Isolated thrombocytopenia with no clinical context to explain it, or a discordant result compared with a prior FBC.

2

Request citrate-tube FBC

Contact the laboratory and request repeat in a sodium citrate (blue-top) tube. This bypasses EDTA-dependent clumping.

3

Request manual blood film

Pathologist review of a fresh smear to assess for platelet clumping, giant platelets, or platelet satellitism. Also evaluates for schistocytes, leucoerythroblastic features, or blasts.

4

Interpret result

If citrate count is normal → pseudothrombocytopenia confirmed. If citrate count remains low → true thrombocytopenia; proceed with full workup below.

💡

Clinical pearl: Some patients have persistent EDTA-dependent pseudothrombocytopenia that recurs with every blood draw. Flag this in the patient's medical record (e.g. My Health Record, GP software alert) to avoid repeated unnecessary investigations.

History & Clinical Examination

A thorough history and focused examination are the cornerstones of thrombocytopenia evaluation. The clinical context often narrows the differential to one or two mechanisms before laboratory results return.

Key History Domains

Domain	Specific Questions	Relevance
Medications	Heparin (including LMWH flushes), antibiotics (cotrimoxazole, linezolid, vancomycin, piperacillin-tazobactam, rifampicin), antiepileptics (valproate, carbamazepine, phenytoin), glycoprotein IIb/IIIa inhibitors (abciximab, tirofiban, eptifibatide), chemotherapeutic agents, quinine, SSRIs, H₂ blockers, herbal supplements	Drug-induced thrombocytopenia is one of the most common reversible causes. Always perform a complete medication reconciliation including over-the-counter and complementary medicines.
Alcohol intake	Quantity (standard drinks/day), duration, history of withdrawal episodes, previous alcohol-related liver disease	Alcohol causes direct marrow suppression and is a major cause of chronic liver disease with portal hypertension and splenomegaly.
Infections	HIV risk factors, hepatitis B/C (IVDU, country of birth, tattoos, blood products before 1990), recent viral illness (EBV, CMV, parvovirus), malaria travel, dengue, Helicobacter pylori symptoms	Viral infections are common causes of transient and chronic thrombocytopenia; H. pylori eradication can resolve ITP in some cases.
Autoimmune disease	SLE, antiphospholipid syndrome, rheumatoid arthritis, autoimmune thyroid disease, Evans syndrome	Thrombocytopenia may be the presenting feature of SLE or APS; autoimmune thyroid disease is associated with ITP.
Liver disease	Known cirrhosis, hepatitis, NAFLD, previous liver function test abnormalities, stigmata of chronic liver disease	Hypersplenism from portal hypertension and reduced thrombopoietin production are the main mechanisms.
Bleeding history	Easy bruising, petechiae, epistaxis, gingival bleeding, menorrhagia, haematuria, melaena, bleeding after procedures/tooth extraction	Severity of bleeding does not always correlate with platelet count but helps determine urgency. Mucosal bleeding is characteristic of platelet disorders.
Nutritional history	Dietary adequacy, B12/folate intake, malabsorption symptoms, strict vegan diet	B12 and folate deficiency cause pancytopenia including thrombocytopenia, often with macrocytosis.
Pregnancy	Gestational age, previous pregnancies, pre-eclampsia symptoms, HELLP syndrome history	Gestational thrombocytopenia, pre-eclampsia/HELLP, and acute fatty liver of pregnancy are pregnancy-specific causes.
Previous blood counts	When was the last normal platelet count? Is this new or chronic?	Helps determine acuity and may identify a temporal relationship with drug exposure or illness.

Focused Clinical Examination

Examination Finding	Suggests
Petechiae (non-blanching, especially lower limbs)	Thrombocytopenia or qualitative platelet disorder; typically appear at <20–30 × 10⁹/L
Purpura, ecchymoses	Significant platelet or coagulation disorder
Splenomegaly	Hypersplenism (liver disease with portal hypertension, myeloproliferative disorders, lymphoproliferative disorders, infections such as EBV)
Hepatomegaly, jaundice, spider naevi, palmar erythema, ascites	Chronic liver disease
Lymphadenopathy	Lymphoproliferative disorder, HIV, infection
Malar rash, oral ulcers, alopecia	Systemic lupus erythematosus
Joint swelling, synovitis	Rheumatological cause of thrombocytopenia
Fever, signs of sepsis	Infection-related thrombocytopenia, DIC
Bony tenderness	Marrow infiltrative process (leukaemia, metastatic malignancy, myelofibrosis)
Pallor	Concurrent anaemia — consider autoimmune haemolytic anaemia (Evans syndrome), DIC, marrow failure, bleeding

💡

Practical tip: Always check both the medication chart (hospital) and the patient's My Health Record/community pharmacy dispense history. Drug-induced thrombocytopenia may involve medications dispensed by different prescribers, including over-the-counter quinine and complementary medicines.

Laboratory Evaluation

Once pseudothrombocytopenia has been excluded, a structured laboratory evaluation is required. The extent of testing is guided by clinical context — a single mild incidental finding in a well patient requires less investigation than severe thrombocytopenia with bleeding.

First-Line Investigations

Essential Full Blood Count (FBC) with manual differential and blood film Confirms thrombocytopenia; assesses concurrent anaemia/leucopenia; evaluates platelet size, red cell morphology (schistocytes → TTP/DIC; macrocytes → B12/folate deficiency or liver disease; teardrops → myelofibrosis), and leucocyte morphology (blasts → leukaemia).

Essential Coagulation Profile — PT/INR, APTT, fibrinogen Prolonged PT and low fibrinogen suggest DIC. Normal coagulation with isolated thrombocytopenia points toward ITP, drug effect, or hypersplenism.

Essential Liver Function Tests (LFTs) Elevated transaminases, low albumin, elevated bilirubin suggest liver disease. Hypoalbuminaemia with thrombocytopenia in a patient with liver disease is common and correlates with Child-Pugh severity. MBS item 66510.

Essential Renal Function (eGFR, creatinine, urea) Chronic kidney disease causes thrombocytopenia via uraemic platelet dysfunction and EPO-related marrow suppression. Acute kidney injury with thrombocytopenia raises concern for TTP/HUS or HRS.

Essential Lactate Dehydrogenase (LDH) Markedly elevated LDH with thrombocytopenia suggests haemolysis (TTP/HUS, DIC, Evans syndrome) or high marrow turnover.

Available HIV serology (4th-generation Ag/Ab assay) HIV causes thrombocytopenia via immune destruction, marrow infiltration, and direct megakaryocyte infection. Screening is recommended in all unexplained thrombocytopenia. Available in all Australian laboratories; MBS item 69316.

Available Hepatitis C antibody (reflex HCV RNA if positive) HCV-associated immune thrombocytopenia can be the presenting feature of chronic hepatitis C. Eradication of HCV may resolve the thrombocytopenia. MBS item 69378.

Available Hepatitis B serology (HBsAg, anti-HBs, anti-HBc) Consider in at-risk populations; chronic HBV can cause thrombocytopenia via immune mechanisms and liver disease. MBS item 69321.

Available Vitamin B12 and Folate Deficiency causes megaloblastic marrow failure with pancytopenia. Consider when macrocytosis (MCV >100 fL) is present on FBC. MBS item 66650/66655.

Second-Line / Context-Specific Investigations

Referral PF4/Heparin Antibody (ELISA) ± Serotonin Release Assay (SRA) For suspected HIT (platelet fall >50%, 5–14 days post-heparin, or acute systemic reaction). ELISA is highly sensitive; SRA is specific and sent to reference laboratory (e.g. RCPA-accredited labs).

Referral ADAMTS13 Activity and Inhibitor For suspected TTP. ADAMTS13 activity <10% is diagnostic. Do NOT delay plasma exchange while awaiting results.

Available Antinuclear Antibody (ANA) ± dsDNA, ENA panel, antiphospholipid antibodies For suspected autoimmune cause (SLE, APS). ANA has high sensitivity for SLE but low specificity.

Available Reticulocyte Count and Haemolysis Screen (haptoglobin, direct antiglobulin test) Elevated reticulocytes with low haptoglobin and elevated bilirubin suggest concurrent haemolysis (Evans syndrome, TTP/DIC, PNH).

Available Thyroid Function Tests (TSH, free T4) Autoimmune thyroiditis is associated with ITP. Hypothyroidism can cause mild thrombocytopenia.

Available Helicobacter pylori Testing (urea breath test or stool antigen) Consider in ITP patients — eradication of H. pylori can lead to platelet recovery in 30–50% of infected ITP patients. Available in primary care; MBS item 69358.

Specialist Bone Marrow Aspiration ± Trephine Biopsy Reserved for unexplained cytopenias (particularly pancytopenia), suspected infiltrative disease (leukaemia, myelofibrosis, metastatic malignancy), or failure to respond to ITP-directed therapy. Performed by haematologist.

💡

Medicare Benefits Schedule (MBS) note: Many first-line investigations (FBC, LFTs, coagulation, viral serology) are funded under Medicare as standard pathology items. Specialised tests such as ADAMTS13, PF4 ELISA, and bone marrow biopsy may require specialist referral for appropriate MBS item coding and authority.

Interpretive Framework

FBC Pattern	Likely Category	Next Steps
Isolated thrombocytopenia, otherwise well	ITP, drug effect, infection, pseudothrombocytopenia	Medication review, viral serology, repeat FBC, consider ITP workup
Pancytopenia (low platelets, WCC, Hb)	Marrow failure (aplastic anaemia, infiltrative disease, megaloblastosis, hypersplenism)	Urgent haematology referral, B12/folate, blood film, bone marrow biopsy
Thrombocytopenia + schistocytes on film	TTP/HUS, DIC, malignant hypertension	Emergency: coag screen, LDH, haptoglobin, blood film, ADAMTS13, treat as TTP until proven otherwise
Thrombocytopenia + prolonged PT/INR, low fibrinogen	DIC	Emergency: treat underlying cause, consider cryoprecipitate and FFP if bleeding
Thrombocytopenia + macrocytosis	B12/folate deficiency, liver disease, alcohol, MDS, drug effect (valproate, MTX)	B12/folate levels, LFTs, alcohol history
Thrombocytopenia + blasts on film	Acute leukaemia	Emergency haematology referral

Red Flag Features & Referral Criteria

Certain clinical and laboratory features demand immediate action — either emergency department presentation or urgent haematology referral. Recognising these red flags is critical, as delays in management of conditions such as TTP, DIC, and acute leukaemia are directly associated with increased mortality.

Emergency Referral — Present to ED or Call Haematology On-Call

🚨

Immediate emergency referral is required for any of the following:

Platelets <20 × 10⁹/L with active bleeding (mucosal, GI, intracranial, genitourinary) — risk of life-threatening haemorrhage.
Platelets <10 × 10⁹/L regardless of symptoms — high risk of spontaneous intracranial haemorrhage.
Suspected TTP/HUS: thrombocytopenia + microangiopathic haemolytic anaemia (schistocytes on film, elevated LDH, low haptoglobin) ± neurological features (confusion, headache, seizures) ± renal impairment. Do NOT wait for ADAMTS13 results; commence plasma exchange emergently.
Suspected DIC: thrombocytopenia with prolonged PT/INR, low fibrinogen, elevated D-dimer, in the context of sepsis, trauma, malignancy, or obstetric emergency.
Acute leukaemia: blasts on blood film, or pancytopenia with constitutional symptoms (fever, weight loss, night sweats) and organomegaly.
Suspected HIT with thrombosis: thrombocytopenia with new arterial or venous thrombosis in the setting of heparin exposure.
Intracranial haemorrhage symptoms (severe headache, focal neurological signs, altered consciousness) in a thrombocytopenic patient.

Urgent Haematology Referral (Within 1–2 Weeks)

Urgent

Platelets 20–50 × 10⁹/L

Without active bleeding but with concerning features: new onset, no clear cause, or progressive decline. Refer within 1–2 weeks.

Setting: Haematology OPD

Urgent

Persistent Thrombocytopenia >4 Weeks

Thrombocytopenia that does not resolve after initial workup and removal of reversible causes. Warrants specialist evaluation.

Setting: Haematology OPD

Urgent

Unexplained Pancytopenia

Multi-lineage cytopenias require bone marrow evaluation; refer regardless of severity.

Setting: Haematology OPD

Routine Haematology Referral

Routine

Unexplained Mild Thrombocytopenia

Platelets 100–150 × 10⁹/L, asymptomatic, no cause identified on initial workup. Repeat FBC in 4–8 weeks; refer if persistent.

Setting: GP follow-up → Haematology if persistent

Routine

Suspected Chronic ITP (Stable)

Platelets >30 × 10⁹/L, no bleeding, after exclusion of secondary causes. Refer for confirmation and monitoring plan.

Setting: Haematology OPD

When to Observe (No Immediate Referral)

✅

Observation with serial FBCs may be appropriate when:

Platelets >100 × 10⁹/L in an asymptomatic patient — repeat FBC in 4–8 weeks.
Mild thrombocytopenia clearly attributable to a reversible cause (e.g. recent infection, medication now ceased) — recheck 2–4 weeks after resolution of the insult.
Stable chronic thrombocytopenia with known cause and haematology follow-up already in place.

⚠️

Safety netting: All patients discharged with thrombocytopenia should receive clear written advice to present immediately if they develop new bruising, petechiae, bleeding (including gum bleeding, blood in urine/stool), severe headache, or confusion. Ensure a follow-up FBC is scheduled.

Initial Management Principles

Management of thrombocytopenia depends entirely on the underlying cause, severity, and clinical context. The following general principles apply while the aetiology is being determined.

Immediate Actions

1

Cease offending agents

If a drug cause is suspected, cease the implicated medication (after risk–benefit assessment with the treating team). For suspected HIT, cease ALL heparin immediately — including LMWH and heparin flushes — and commence an alternative anticoagulant (argatroban or fondaparinux).

2

Treat underlying cause

Sepsis → antibiotics and source control. B12/folate deficiency → replacement. Liver disease → optimise management. Immune cause → consider corticosteroids under specialist guidance.

3

Bleeding precautions

Avoid IM injections, arterial punctures, and NSAIDs/antiplatelet agents when platelets are <50 × 10⁹/L. Avoid contact sports. Use electric razors. Apply pressure to venepuncture sites for ≥5 minutes.

4

Platelet transfusion threshold

Transfuse platelets for active bleeding when platelets <50 × 10⁹/L, or prophylactically when <10 × 10⁹/L (or <20 × 10⁹/L with additional risk factors). Do NOT transfuse in TTP (worsens thrombosis) or in isolated ITP unless life-threatening bleeding.

Platelet Transfusion Guidance

🩸

Platelet Concentrate (Apheresis or Pooled)

Australian Red Cross Lifeblood · Blood product

Indication (prophylactic) Platelets <10 × 10⁹/L stable patient; <20 × 10⁹/L with fever/infection/surgical site

Indication (therapeutic) Active bleeding with platelets <50 × 10⁹/L

Dose 1 adult therapeutic dose (ATD) — expected increment ~20–40 × 10⁹/L

Contraindicated TTP (worsens thrombosis); HIT (use alternative anticoagulant); ITP unless life-threatening bleeding

PBS status ✔ Funded via Lifeblood (no PBS)

Common Cause-Specific Therapies (Summary)

Cause	First-Line Therapy	Notes
ITP (immune thrombocytopenia)	Corticosteroids (prednisolone 1 mg/kg/day PO for 1–2 weeks then taper, or dexamethasone 40 mg/day PO/IV for 4 days)	Haematologist-directed; IV immunoglobulin for severe bleeding or pre-procedure.
HIT (Type II)	Cease heparin, commence non-heparin anticoagulant (fondaparinux 7.5 mg SC OD or argatroban IV infusion)	Do NOT give warfarin until platelets >150 × 10⁹/L. Do NOT give LMWH. Haematology co-management essential.
TTP	Emergency plasma exchange + corticosteroids (methylprednisolone 1 g IV daily for 3 days) ± caplacizumab	Do NOT transfuse platelets. Transfer to centre with apheresis capability. Haematology emergency.
Sepsis/DIC	Treat underlying infection; supportive care with blood products if bleeding	Platelet transfusion threshold 10–20 × 10⁹/L if stable, 50 × 10⁹/L if bleeding.
Drug-induced	Cease offending drug; platelets typically recover in 5–7 days	Some drugs (e.g. heparin, quinine) may cause rapid onset; others (valproate) are dose-dependent.
Hypersplenism	Treat underlying liver disease; avoid splenectomy unless refractory	Typically platelets 50–100 × 10⁹/L; rarely causes bleeding.
B12/Folate deficiency	Hydroxocobalamin 1 mg IM (alternate days for 2 weeks, then every 2–3 months); folic acid 5 mg PO daily	Monitor for reticulocytosis at 1 week and FBC improvement by 4–8 weeks.

Special Populations

🤰

Pregnancy

Gestational thrombocytopenia

Most common cause in pregnancy (70–80%); typically mild (>70 × 10⁹/L), occurs in late 2nd/3rd trimester, no treatment required, resolves postpartum.

Pre-eclampsia / HELLP

Platelets <100 × 10⁹/L with hypertension, proteinuria, elevated LFTs, haemolysis. Obstetric emergency — delivery is definitive treatment. Refer to obstetric medicine/haematology.

ITP in pregnancy

Maintain platelets >30 × 10⁹/L (or >50 × 10⁹/L in 3rd trimester). First-line: corticosteroids or IV immunoglobulin. Avoid splenectomy. Neonatal platelet count should be checked at birth.

Medication safety

Avoid mycophenolate, methotrexate, danazol in pregnancy. Corticosteroids and IV immunoglobulin are considered safe. Rituximab — avoid in first trimester if possible.

👶

Paediatrics

Neonatal alloimmune thrombocytopenia (NAIT)

Platelet antigen incompatibility between mother and foetus; can cause severe thrombocytopenia (<20 × 10⁹/L) and intracranial haemorrhage. Treat with HPA-compatible platelets. Refer to neonatology/paediatric haematology.

Childhood ITP

Peak age 2–6 years; often post-viral, self-limiting (>80% resolve within 6 months). Treat only if significant bleeding (IV immunoglobulin or corticosteroids). Avoid aspirin and NSAIDs. Refer to paediatric haematology.

Kawasaki disease

Thrombocytosis (not thrombocytopenia) is typical, but early phase may show mild thrombocytopenia. Important to distinguish from sepsis and ITP.

Infection-related

Viral infections (EBV, CMV, parvovirus, dengue, COVID-19) are the most common cause of childhood thrombocytopenia after ITP. Usually self-limiting.

👴

Elderly

Polypharmacy risk

Elderly patients are at higher risk of drug-induced thrombocytopenia due to polypharmacy. Review all medications, including over-the-counter and herbal products. Consider medication interaction effects.

Myelodysplastic syndrome (MDS)

Incidence increases sharply after age 70; isolated or multi-lineage cytopenias. Blood film may show dysplastic features. Bone marrow biopsy required for diagnosis.

Chronic liver disease

Increasing prevalence with age; hypersplenism is a common mechanism. Consider occult alcohol use and NAFLD/NASH.

Bleeding risk assessment

Consider HAS-BLED score in patients on anticoagulants. Fall risk is higher — ensure adequate platelet count for safe mobilisation (generally >30 × 10⁹/L).

🫘

Renal Impairment

Uraemic thrombocytopathy

CKD/ESKD causes qualitative platelet dysfunction even with normal counts. Desmopressin (DDAVP) 0.3 μg/kg IV or cryoprecipitate may be used for active bleeding or pre-procedure. Ensure adequate dialysis.

Drug dose adjustments

Many medications used in thrombocytopenia workup require renal dose adjustment (e.g. fondaparinux contraindicated if eGFR <30 mL/min). Check individual product information.

HUS

Atypical HUS (complement-mediated) or Shiga toxin–associated HUS presents with AKI, thrombocytopenia, and MAHA. Manage in nephrology/haematology partnership; eculizumab for atypical HUS.

🫁

Hepatic Impairment

Portal hypertension / Hypersplenism

The most common mechanism of thrombocytopenia in liver disease. Typically platelets 50–100 × 10⁹/L; rarely causes bleeding. Correlates with severity of portal hypertension rather than liver synthetic function.

Reduced thrombopoietin production

The failing liver produces less thrombopoietin. Thrombopoietin receptor agonists (e.g. avatrombopag, lusutrombopag) are PBS-listed (Authority Required) for chronic liver disease patients undergoing procedures — managed by hepatologist/haematologist.

Coagulopathy assessment

Liver disease causes complex coagulation derangement (elevated PT/INR, low fibrinogen, elevated D-dimer). INR alone does not reliably predict bleeding risk in liver disease. Viscoelastic testing (ROTEM/TEG) may be useful in procedural settings.

🛡️

Immunocompromised

HIV-associated thrombocytopenia

Immune-mediated destruction, direct megakaryocyte infection, and opportunistic infections. Treatment of HIV with ART often resolves thrombocytopenia. Consider ITP-like treatment if severe. Refer to infectious diseases/haematology.

Post-transplant

Drug-induced (mycophenolate, tacrolimus, ganciclovir), infections (CMV, EBV), PTLD, and TMA. Workup requires transplant team involvement.

Chemotherapy-induced

Expected nadir based on regimen; transfusion support as needed. Persistent or severe thrombocytopenia may indicate marrow recovery failure. Refer to treating oncologist/haematologist.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Thrombocytopenia in Aboriginal and Torres Strait Islander Australians must be considered within the broader context of significant health disparities, higher prevalence of certain underlying conditions, and barriers to healthcare access. A culturally safe, strengths-based approach that acknowledges the social determinants of health is essential.

Chronic liver disease

Aboriginal and Torres Strait Islander Australians have rates of liver-related hospitalisation and mortality approximately 3–4 times higher than the non-Indigenous population (AIHW 2023). Chronic hepatitis B is endemic in some remote communities, and alcohol-related liver disease remains a significant contributor. Thrombocytopenia from hypersplenism and reduced thrombopoietin production is common. Liver disease staging with FIB-4 or transient elastography should be pursued where available.

Hepatitis B prevalence

Chronic hepatitis B prevalence in Aboriginal and Torres Strait Islander Australians is estimated at 3–5%, with higher rates in the Northern Territory and remote communities. Universal hepatitis B screening should be offered. Antiviral treatment (entecavir or tenofovir) can improve platelet counts by reducing liver inflammation and fibrosis. PBS Authority Required for antiviral therapy.

Hepatitis C and injecting drug use

HCV prevalence is disproportionately high. Direct-acting antiviral (DAA) therapy is available under PBS and can achieve >95% cure rates, with subsequent improvement in platelet counts. Encourage HCV testing and treatment as part of thrombocytopenia workup.

Helicobacter pylori infection

Prevalence of H. pylori is significantly higher in remote Aboriginal and Torres Strait Islander communities (up to 70–90% in some studies). In patients with ITP, H. pylori eradication may improve platelet counts. Urea breath test or stool antigen testing should be considered.

Rheumatic fever and RHD

Rheumatic heart disease (RHD) requiring long-term antibiotic prophylaxis and anticoagulation is much more common in Aboriginal and Torres Strait Islander Australians. Thrombocytopenia in these patients requires careful assessment of the interaction between medications and the underlying disease.

Remote and rural access

Many Aboriginal and Torres Strait Islander Australians live in remote areas with limited access to haematology specialists, pathology services, and hospital-level care. Telehealth consultations with haematology services (e.g. via the Royal Darwin Hospital or Alice Springs Hospital) should be facilitated. Point-of-care testing (iSTAT or similar) may assist in urgent assessments where laboratory turnaround is prolonged.

Cultural safety

Engage Aboriginal and Torres Strait Islander health workers and liaison officers in all stages of assessment and management. Use plain language and visual aids. Acknowledge family and community in decision-making. Ensure appropriate gender-matching for sensitive examinations where preferred. Avoid assumptions about lifestyle factors — focus on strengths-based, non-judgemental care.

Follow-up and continuity of care

Ensure robust recall systems for follow-up FBCs and specialist appointments. Coordinate with Aboriginal Community Controlled Health Organisations (ACCHOs) for continuity. Use Closing the Gap PBS co-payment measures to reduce medication costs. Document thrombocytopenia and follow-up plans clearly in shared health records (e.g. My Health Record).

Quick Reference — Differential Diagnosis by Mechanism

Mechanism	Examples	Clues
Decreased production	Aplastic anaemia, MDS, leukaemia, marrow infiltration (myelofibrosis, metastatic cancer), B12/folate deficiency, chemotherapy, radiation, alcohol	Pancytopenia, macrocytosis, leucoerythroblastic film, B symptoms
Immune destruction	ITP (primary or secondary), SLE, APS, Evans syndrome, drug-induced immune (heparin, quinine), post-infectious, CLL-associated	Isolated thrombocytopenia, acute onset, young female or post-viral
Non-immune destruction	TTP/HUS, DIC, mechanical (prosthetic valves, ECMO), HELLP, malignant hypertension	Schistocytes on film, elevated LDH, low haptoglobin, coagulopathy
Sequestration	Hypersplenism (portal hypertension, myeloproliferative disorders, storage diseases, infections causing massive splenomegaly)	Palpable spleen, liver disease stigmata, typically mild–moderate thrombocytopenia
Dilutional	Massive transfusion, aggressive IV fluid resuscitation	Recent large-volume transfusion/fluid administration in acute setting

📚 References

1. Arnold DM, Nazi I, Kelton JG. Approach to the diagnosis of thrombocytopenia in adults. In: Post TW, ed. UpToDate. Waltham, MA; 2024.
2. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866.
3. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323–335.
4. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):311S–337S.
5. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Detailed Analyses. Canberra: AIHW; 2023.
6. Australian Red Cross Lifeblood. Clinical Guidelines for Platelet Transfusion. Melbourne: Lifeblood; 2023. Available at: lifeblood.com.au.
7. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511–6521.
8. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817.
9. Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009;113(6):1231–1240.
10. McCrae KR. Thrombocytopenia in pregnancy: differential diagnosis, pathogenesis, and management. Blood Rev. 2003;17(1):7–14.
11. Koziol J, Luck J, Jabour M, et al. Hepatitis B prevalence and management in Aboriginal and Torres Strait Islander communities in the Northern Territory. Aust N Z J Public Health. 2022;46(3):314–320.
12. Ponziani FR, Gasbarrini A, Pompili M, et al. Helicobacter pylori and immune thrombocytopenia: a systematic review and a critical appraisal. Intern Emerg Med. 2020;15(3):411–421.
13. National Health and Medical Research Council (NHMRC). Australian Clinical Practice Guidelines for Immune Thrombocytopenia. Canberra: NHMRC; 2021.
14. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018;131(8):845–854.
15. Sullivan PW, Ghushchyan V. Drug-induced thrombocytopenia: a systematic review and meta-analysis of case reports. Pharmacotherapy. 2023;43(5):408–422.